Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:45 AM
Ignite Modification Date:
2025-12-25 @ 2:45 AM
NCT ID:
NCT06271733
Eligibility Criteria:
Inclusion Criteria:
* Veterans or service members between the ages of 18 and 65 who are attending the 2- week Intensive Outpatient Program at the Road Home Program and have not had significant PTSD symptom change based on the PCL-5 during the first week of treatment.
* Participants with an HDRS-21 score ≤ 26 at screening visit
Exclusion Criteria:
* Individuals with implants and non-removable metals which prevent them from safely receiving TMS, including:
* Aneurysm clips or coils
* Stents in the head, neck, or brain
* Deep brain stimulators
* Metallic implants in the head, neck, or brain (braces and dental implants do not interfere and are safe for TMS)
* Shrapnel or bullet fragments in or near the head
* Facial tattoos with metallic or magnetic-sensitive ink
* Other metal devices or ferromagnetic objects implanted in or near the head
* Pacemakers, intra-cardiac lines, or implanted medical pumps
* Individuals with a history of seizures or epilepsy (except those therapeutically induced by ECT)
* Individuals diagnosed with major, chronic mental health illnesses such as Psychotic Disorders, Bipolar Disorders, and Obsessive Compulsive Disorder
* Individuals with a history of substance abuse within the past six months
* Individuals with significant neurological disorders such as Parkinson's disease, Huntington's chorea, and Multiple sclerosis
* Individuals with unstable physical disease, such as unstable cardiac diseases
* Individuals currently on Benzodiazepine at a dose higher than 3mg or Lorazepam or equivalent.
* Women who are breastfeeding or pregnant
* Individuals with previous TMS treatment
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT06271733
Study Brief:
Protocol Section:
NCT06271733